Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

SSRI use not associated with cataract risk

30 Oct 2017

Use of selective serotonin reuptake inhibitors (SSRIs) does not appear to increase the risk of cataract, reports a recent study.

Researchers identified a total of 206,931 cataract cases matched with the same number of controls. There was no association between current long-term use of SSRI (≥20 prescriptions) and an increased cataract risk (adjusted odds ratio [aOR], 0.99; 95 percent CI, 0.94 to 1.03). On the other hand, a slightly increased risk of cataract was seen for long-term SSRI users compared with nonusers in a subgroup of patients aged 40 to 64 years.

“The slightly increased OR for individuals younger than 65 years of age in association with long-term SSRI use needs to be investigated in further studies,” researchers said.

In this case-control study, the authors derived the participants from the UK-based Clinical Practice Research Datalink (CPRD). Included were patients with first-time cataract aged ≥40 years between 1995 and 2015 and an equal number of cataract-free controls matched on age, sex, general practice, date of cataract recording (ie, index date) and years of history in the CPRD before the index date.

Conditional logistic regression analyses were conducted, adjusting for body mass index, smoking, hypertension, diabetes and systemic steroid use. The number of SSRI prescriptions and prescriptions for other antidepressant drugs were the exposure of interest. Mutually exclusive use of single SSRI substances was explored.

The index data was shifted backwards by 2 years in sensitivity analyses. Also, analyses were restricted to cases and controls without a prior glaucoma diagnosis.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]